Tixagevimab-Cilgavimab Treatment and Cardiovascular Events: Immortal Time Bias

被引：1
|
作者：
Montastruc, Francois [1 ,2 ,3 ]
de Canecaude, Claire [1 ,2 ]
机构：
[1] Toulouse Univ Hosp CHU, Fac Med, Ctr PharmacoVigilance & Pharmacoepidemiol, Dept Med & Clin Pharmacol, Toulouse, France
[2] Toulouse Univ Hosp, Ctr Invest Clin 1436, Team PEPSS Pharmacol Populat cohorteS & biobanqueS, Toulouse, France
[3] Toulouse Univ Hosp, Fac Med, Ctr PharmacoVigilance & Pharmacoepidemiol, Dept Med & Clin Pharmacol, 37 Allees Jules Guesde, F-31000 Toulouse, France
来源：
CLINICAL INFECTIOUS DISEASES | 2023年 / 76卷 / 11期
关键词：
D O I：
10.1093/cid/ciad089
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：2044 / 2045
页数：2
相关论文
共 50 条
  • [21] The effect of tixagevimab-cilgavimab on clinical outcomes in patients with COVID-19: A systematic review with meta-analysis
    Wang, Yong
    Zheng, Jun
    Zhu, Kongfu
    Xu, Chengshi
    Wang, Daping
    Hou, Mengzhuo
    JOURNAL OF INFECTION, 2023, 86 (01) : E15 - E17
  • [22] Safety of intramuscular tixagevimab-cilgavimab (Evusheld®) administration in patients at risk of iatrogenic haematoma due to haematological disorders
    Malherbe, Jacques A. J.
    Misko, Jeanie
    Jayawardena, Nishani K.
    Rawlins, Matthew D. M.
    Manning, Laurens
    Purtill, Duncan
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2024,
  • [23] Cardiac and vascular serious adverse events following tixagevimab- cilgavimab
    Piszczek, Jolanta
    Murthy, Srinivas
    Afra, Kevin
    LANCET RESPIRATORY MEDICINE, 2023, 11 (01): : E5 - E6
  • [24] A single-center review of pre-exposure prophylaxis with tixagevimab-cilgavimab in solid organ transplant recipients
    Morado, Faiza
    Davoudi, Roland
    Kawewat-Ho, Pnada
    Nanda, Neha
    Cartus, Rachel
    Shaikh, Suhail A.
    TRANSPLANT INFECTIOUS DISEASE, 2023, 25 (04)
  • [25] Molecular Characterization of AZD7442 (Tixagevimab-Cilgavimab) Neutralization of SARS-CoV-2 Omicron Subvariants
    Roe, Tiffany L.
    Brady, Tyler
    Schuko, Nicolette
    Nguyen, Amy
    Beloor, Jagadish
    Guest, Johnathan D.
    Aksyuk, Anastasia A.
    Tuffy, Kevin M.
    Zhang, Tianhui
    Streicher, Katie
    Kelly, Elizabeth J.
    Kijak, Gustavo H.
    MICROBIOLOGY SPECTRUM, 2023, 11 (02)
  • [26] Prophylactic effect of tixagevimab-cilgavimab on COVID-19 infection and death in Japanese patients with B cell lymphoma
    Tatetsu, Hiro
    Higuchi, Yusuke
    Shichijo, Takafumi
    Oda, Kazutaka
    Nakata, Hirotomo
    Yasunaga, Jun-Ichirou
    Nosaka, Kisato
    Matsuoka, Masao
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2023, 118 (02) : 303 - 305
  • [27] Retrospective Analysis of a Real-Life Use of Tixagevimab-Cilgavimab plus SARS-CoV-2 Antivirals for Treatment of COVID-19
    Capoluongo, Nicolina
    Mascolo, Annamaria
    Bernardi, Francesca Futura
    Sarno, Marina
    Mattera, Valentina
    di Flumeri, Giusy
    Pustorino, Bruno
    Spaterella, Micaela
    Trama, Ugo
    Capuano, Annalisa
    Perrella, Alessandro
    PHARMACEUTICALS, 2023, 16 (10)
  • [28] Real-world experience of tixagevimab-cilgavimab pre-exposure prophylaxis in orthotopic heart transplant recipients
    Ordaya, Eloy E.
    Higgins, Eibhlin M.
    Vergidis, Paschalis
    Razonable, Raymund R.
    Beam, Elena
    TRANSPLANT INFECTIOUS DISEASE, 2023, 25 (03)
  • [29] Response to letter entitled: Tixagevimab/cilgavimab pre-exposure prophylaxis and breakthrough infection risk in vaccinated solid organ transplant recipients: Concern for immortal time bias effect
    Al Jurdi, Ayman
    Morena, Leela
    Riella, Leonardo V.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2023, 23 (03) : 451 - 452
  • [30] Tixagevimab-Cilgavimab Rollout on Common Variable Immunodeficient Patients: Early Lessons from an Academic Allergy and Immunology Clinic
    Dluzynski, Daniela
    Al-Shaikhly, Taha
    Henao, Maria Paula
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 151 (02) : AB26 - AB26
12345